Abstract
Objective. Specific activity of an antiplatelet drug of indolinone series (codenamed DI) was studied in vitro in a model of ADP-induced platelet aggregation in vitro and in vivo in a model of streptozotocininduced diabetes mellitus in rats.
 Material and Methods. Acetylsalicylic acid and dipyridamole were used as reference drugs. In vitro tests have demonstrated that DI exhibits antiplatelet activity in a wide range of concentrations (0,75×10-6 – 1.5×10-5 М, р<0,05), being comparable to acetylsalicylic acid and dipyridamole. In vivo tests have demonstrated dose-dependent antiplatelet activity of DI in doses of 2,5 – 20 mg/kg (21-14 %).
 Results and Discussion.Increasing the dose of DI above 10 mg/kg doesn’t increase its antiplatelet activity. After multiple oral administration to rats with streptozotocin-induced diabetes mellitus in 10 mg/kg dose, DI has exhibited antiplatelet activity, reducing the platelet aggregation rate to that of the control group (р<0,05).
 Conclusion. Thus, DI isapromisingcompound for furtherdevelopmentof an antiplatelet drug with new mechanism of action
 Bangladesh Journal of Medical Science Vol.18(3) 2019 p.574-576
Highlights
Antiplatelet therapy is very important in preventing cardiovascular diseases[1]
In addition to the well-known adverse effects of the most popular antiplatelet drugs acetylsalicylic acid (ASA) and clopidogrel a new problem arose in recent years: antiplatelet drug resistance[2]
Control group animals received an equal volume of carboxymethyl cellulose
Summary
Antiplatelet therapy is very important in preventing cardiovascular diseases[1]. in addition to the well-known adverse effects of the most popular antiplatelet drugs acetylsalicylic acid (ASA) and clopidogrel a new problem arose in recent years: antiplatelet drug resistance[2]. Study goal – Assess the action of the new compound DI on platelet aggregation invitro and invivo in intact animals with experimental diabetes mellitus[10]. 1. V.V. Bykov, Siberian State Medical University (SSMU) of Russian Ministry of Health, Tomsk, Russia 2. Correspondence to: V.V. Byko, Siberian State Medical University (SSMU) of Russian Ministry of Health, Tomsk, Russia.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
